placeholder image
D. H. Yang All authors
About
Publications While At HealthPartners
Highlights
selected publications
Journal Article
  • Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age. 
    Vaccine. 2025
  • Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States. 
    Clinical Infectious Diseases. 2025
  • Interim estimates of 2024-2025 seasonal influenza vaccine effectiveness - four vaccine effectiveness networks, United States, October 2024-February 2025. 
    MMWR: Morbidity and Mortality Weekly Report. 2025
  • Methods to adjust for confounding in test-negative design COVID-19 effectiveness studies: simulation study. 
    JMIR formative research. 2025
  • Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 
    Journal of Infectious Diseases. 2024
  • Interim estimates of 2023-24 seasonal influenza vaccine effectiveness - United States. 
    MMWR: Morbidity and Mortality Weekly Report. 2024
  • Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders. 
    Influenza and other respiratory viruses. 2024
  • Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 
    Clinical Infectious Diseases. 2024
  • Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2023
  • Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 
    Vaccine. 2023
  • Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 
    JAMA network open. 2023
  • Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance. 
    Journal of Infectious Diseases. 2023
  • Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 
    Journal of Infectious Diseases. 2023
  • Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 
    American Journal of Transplantation. 2022
  • Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 
    BMJ (Clinical research ed.). 2022
  • Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
    • Contact
    full name
  • D. H. Yang
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.
    Collaboration